IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial
医学
随机对照试验
透析
内科学
重症监护医学
作者
Glenn M. Chertow,Anna Marie Chang,G. Michael Felker,Mark Heise,Elena Velkoska,Bengt Fellström,David M. Charytan,Regina Clementi,C. Michael Gibson,Shaun G. Goodman,Meg Jardine,Adeera Levin,Yuliya Lokhnygina,Jenny Mears,Roxana Mehran,Peter Stenvinkel,Angela Yee‐Moon Wang,David C. Wheeler,Carmine Zoccali,Paul M. Ridker,Kenneth W. Mahaffey,Pierluigi Tricoci,Myles Wolf
出处
期刊：Nature Medicine [Springer Nature] 日期：2024-05-25卷期号：30 (8): 2328-2336被引量：9
Inflammation mediated by interleukin-6 (IL-6) is strongly associated with cardiovascular risk. Here we evaluated clazakizumab, a monoclonal antibody targeting the IL-6 ligand, in a phase 2b dose-finding study. Adults with cardiovascular disease and/or diabetes receiving maintenance dialysis with high-sensitivity C-reactive protein (hs-CRP) ≥ 2 mg l
毛豆
Ganlou
sissiarno
lalala
丰知然
123
良辰
cocolu
mhl11
36456657
模糊中正
彭于彦祖
Singularity
Billy
shinysparrow
杳鸢
tuanheqi
坚强的广山
宜醉宜游宜睡
竹筏过海
皖公网安备34019202002308
